SCHEMBL1365863

SCHEMBL1365863

C1=NCCN2c3ccccc3CC12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.41
HTR2A P28223 2/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTR2B P41595 2/20 0.33
GAA P10253 1/20 0.33
GFER P55789 1/20 0.33
AADAT Q8N5Z0 2/20 0.33
NOTUM Q6P988 2/20 0.33
GOT1 P17174 1/20 0.33
KYAT1 Q16773 1/20 0.33
KYAT3 Q6YP21 1/20 0.33
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364392 0.70 HTR2C (0.53) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL13246537 0.70 CTSD (0.42) HTR2CHTR2AMEN1KMT2AAADAT
SCHEMBL14382060 0.69 HTR2C (0.41) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL17887724 0.68 NOS1 (0.45) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL5835687 0.66 HTR2C (0.40) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL437838 0.64 HTR2C (0.39) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL3467602 0.63 NOTUM (0.39) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL3050637 0.62 SRD5A1 (0.36) HTR2CHTR2AHTR2BAADATNOTUM
SCHEMBL10153943 0.62 HTR2C (0.65) HTR2CHTR2AMEN1KMT2AHTR2B
SCHEMBL11179442 0.61 HTR2C (0.42) HTR2CHTR2AMEN1KMT2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases INCYTE HOLDINGS CORPORATION (US) 2019-03-12 US disclosed
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION 2018-06-07 US disclosed
US-20140187530-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION (US) 2014-07-03 US disclosed
US-8637497-B2 AZA spiro alkane derivatives as inhibitors of metalloproteases INCYTE CORPORATION (US) 2014-01-28 US disclosed
US-20110288068-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES INCYTE CORPORATION 2011-11-24 US disclosed
US-8039471-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases INCYTE CORPORATION (US) 2011-10-18 US disclosed
US-20090124649-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES INCYTE CORPORATION (US) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288068-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES MMP9, MMP3, MMP12 HTR2C 3651/4885HTR2A 3178/4885MEN1 1892/4885
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases MMP9, MMP3, MMP12 HTR2C 3651/4885HTR2A 3178/4885MEN1 1892/4885
US-20090124649-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES MMP9, MMP3, MMP12 HTR2C 3651/4885HTR2A 3178/4885MEN1 1892/4885
US-20140187530-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 HTR2C 3651/4885HTR2A 3178/4885MEN1 1892/4885
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 HTR2C 3651/4885HTR2A 3178/4885MEN1 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.